poudre et solvant pour solution injectable / pour perfusion
Sponsors
Institut Curie, Delcath Systems Inc.
Conditions
Ocular conservative treatment for retinoblastomaRefractory Metastatic Breast Cancer with Liver Dominant DiseaseRefractory Metastatic Colorectal Cancer with Liver Dominant Disease
Phase 2
RETINO 2018: conservative treatment for retinoblastoma: efficacy of the new management strategies and visual outcome
RecruitingCTIS2024-514025-30-00
Start: 2021-03-25Target: 225Updated: 2024-05-31
An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Trifluridine–tipiracil plus Bevacizumab Versus Trifluridine–tipiracil plus Bevacizumab Alone in Patients with Refractory Metastatic Colorectal Cancer with Liver Dominant Disease
RecruitingCTIS2024-520356-24-00
Start: 2025-12-01Target: 35Updated: 2025-11-21
An Open-label, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Induction Treatment with Melphalan/HDS Followed by Consolidation Treatment with Eribulin or Vinorelbine or Capecitabine Versus Eribulin or Vinorelbine or Capecitabine Alone in Patients with Metastatic Breast Cancer with Liver Dominant Disease
Not yet recruitingCTIS2025-521966-91-00
Target: 3Updated: 2026-02-04